Venture Opportunity Fund Atlas Purchases 17,857 Shares of Korro Bio, Inc. (NASDAQ:KRRO) Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Venture Opportunity Fund Atlas bought 17,857 shares of the stock in a transaction that occurred on Monday, April 22nd. The shares were acquired at an average cost of $56.00 per share, with a total value of $999,992.00. Following the completion of the purchase, the insider now owns 195,074 shares in the company, valued at approximately $10,924,144. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Korro Bio Trading Down 7.3 %

NASDAQ:KRRO opened at $62.99 on Thursday. Korro Bio, Inc. has a twelve month low of $9.15 and a twelve month high of $97.91. The business’s 50 day moving average price is $64.40. The firm has a market cap of $505.18 million, a P/E ratio of -0.67 and a beta of 2.18.

Wall Street Analyst Weigh In

KRRO has been the subject of a number of research reports. Piper Sandler reissued an “overweight” rating and set a $180.00 target price on shares of Korro Bio in a research note on Wednesday, March 27th. BMO Capital Markets reaffirmed an “outperform” rating and set a $120.00 price target on shares of Korro Bio in a research report on Tuesday, March 26th. Royal Bank of Canada upped their price target on Korro Bio from $70.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 27th. Finally, HC Wainwright upped their price target on Korro Bio from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, March 28th.

Institutional Investors Weigh In On Korro Bio

Large investors have recently made changes to their positions in the stock. North Star Investment Management Corp. acquired a new stake in shares of Korro Bio in the 4th quarter valued at approximately $48,000. Monashee Investment Management LLC acquired a new stake in shares of Korro Bio in the 4th quarter valued at approximately $4,352,000. 72 Investment Holdings LLC acquired a new stake in shares of Korro Bio in the 4th quarter valued at approximately $13,269,000. Eventide Asset Management LLC acquired a new stake in shares of Korro Bio in the 4th quarter valued at approximately $26,185,000. Finally, Atlas Venture Life Science Advisors LLC acquired a new stake in shares of Korro Bio in the 4th quarter valued at approximately $53,648,000. Institutional investors and hedge funds own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.